Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study.
Long, Georgina V. , Akkooi, Alexander Christopher Jonathan Van, Karakousis, Giorgos C. , Vetto, John T. , Ascierto, Paolo A. , Dummer, Reinhard, Schachter, Jacob , Carlino, Matteo S. , Akkooi, Alexander C. J. van , Long, Georgina V , Bagge, Roger Olofsson , Holmberg, Carl Jacob , Hieken, Tina J. , Zager, Jonathan S. , Pallan, Lalit , Gyorki, David E. , Dummer, Reinhard , Hui, Jane Yuet Ching , Helgadóttir, Hildur , Kroon, Hidde M. , Rothermel, Luke D. , Broman, Kristy K. , Ny, Lars

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 9569-9569

10.1200/jco.2022.40.16_suppl.9569 Get It

9569 Background: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease. The aim of this study was to analyze the outcome of patients with ITM treated with ICI based on data from a large cohort of patients treated at international high‐volume melanoma centers. Methods: A multicenter retrospective cohort study of patients treated between January 2015 and December 2020 from Australia, Europe, and USA, evaluating treatment with ICI for ITM with or without nodal involvement (AJCC8 N1c, N2c and N3c) and without distant disease (M0). Patients were treated with PD-1 inhibitor (nivolumab or pembrolizumab) and/or CTLA-4 inhibitor (ipilimumab). We assessed response rates, progression-free survival (PFS), melanoma-specific survival (MSS) and overall survival (OS). Results: A total of 287 patients from 21 institutions in 8 countries were included. Immunotherapy was first-line treatment in 64 (22%) patients. Monotherapy with a PD-1 or CTLA-4 inhibitor was given in 233 (81%) and 23 (8%) patients respectively, while 31 (11%) received both in combination. Overall response rate was 56%, complete response (CR) rate 36% and progressive disease (PD) rate 32%. Median PFS was 10 months (95% CI 7.4-12.6 months) with a 1-, 2- and 5-year PFS rate of 48%, 33% and 18% respectively. Median MSS was not reached, and the 1-, 2- and 5-year MSS rates were 95%, 83% and 71% respectively. Conclusions: Systemic immunotherapy is an effective treatment for melanoma ITM. Future studies should evaluate the optimal role for systemic immunotherapy in the context of multimodality therapy including locoregional treatments such as surgery, intralesional therapy, and regional therapies.
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.
Ansell, Stephen M. , Kim, Won Seog , Gallamini, Andrea , Ramchandren, Radhakrishnan , Friedberg, Jonathan W. , Eom, Hyeon Seok, Dong, Cassie, Campana, Frank, Fenton, Keenan , Puhlmann, Markus , Straus, David J. , Connors, Joseph M. , Radford, John , Advani, Ranjana H. , Hutchings, Martin , Evens, Andrew M. , Smolewski, Piotr , Savage, Kerry J. , Bartlett, Nancy L. , Eom, Hyeon‐Seok , Abramson, Jeremy S.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 7503-7503

10.1200/jco.2022.40.16_suppl.7503 Get It

7503 Background: To date, an overall survival (OS) benefit from upfront treatment for new treatment combinations over existing approaches has rarely been shown in first-line classical Hodgkin lymphoma (cHL). With the introduction of newer active therapies for relapsed/refractory disease, demonstration of improved OS with first-line therapy has been challenging. In ECHELON-1 (NCT01712490), 5-year follow-up analyses supported the long-term progression-free survival (PFS) benefit with first-line brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with stage III/IV cHL, independent of interim positron emission tomography status. A+AVD had a manageable long-term safety profile, with numerically fewer second malignancies and a greater number of pregnancies reported vs ABVD (Connors et al, NEJM 2018; Straus et al, Lancet Haematol 2021). We report a prespecified OS analysis after approximately 6 years’ follow-up (cut-off, June 1, 2021). Methods: Pts were randomized 1:1 to receive up to 6 cycles of A+AVD (n = 664) or ABVD (n = 670) on day 1 and 15 every 28 days. OS was the key secondary endpoint and was an event-driven, pre-specified, alpha-controlled analysis in the intention to treat population. Results: At a median follow-up of 73 months, 39 and 64 OS events occurred in A+AVD and ABVD arms, respectively: OS significantly favored A+AVD vs ABVD (HR 0.590; 95% confidence interval [CI] 0.396–0.879; p = 0.009). Estimated 6-year OS rates (95% CI) were 93.9% (91.6–95.5) vs 89.4% (86.6–91.7) with A+AVD vs ABVD, respectively. There was a consistent OS benefit for A+AVD vs ABVD across prespecified subgroups. The 6-year PFS estimate was 82.3% (79.1–85.0) vs 74.5% (70.8–77.7) with A+AVD vs ABVD, respectively (HR 0.678 [95% CI 0.532–0.863]). Overall, A+AVD had a comparable long-term safety profile to ABVD. Treatment-emergent peripheral neuropathy continued to resolve or improve in both arms, with 86% (379/443) and 87% (249/286) of cases in the A+AVD and ABVD arms either completely resolving (72% vs 79%) or improving (14% vs 8%) by last follow-up. Fewer second malignancies were reported in the A+AVD vs ABVD arm (23 vs 32). More female patients reported pregnancy (49 vs 28) or live births (42 vs 19 in females) in the A+AVD vs the ABVD arm; no stillbirths were reported. No new safety signals were identified. Conclusions: A+AVD treatment resulted in a statistically significant 41% reduction in the risk of death vs ABVD, with a manageable safety profile consistent with prior reports. These outcomes confirm A+AVD as a preferred option for pts with previously untreated stage III/IV cHL. Clinical trial information: NCT01712490.
Association of neighborhood socioeconomic disadvantage and cognitive impairment
Vassilaki, Maria , Aakre, Jeremiah A. , Castillo, Anna , Wilson, Patrick M. , Kremers, Walter K. , Geda, Yonas E. , Alhurani, Rabe E., Graff‐Radford, Jonathan , Vemuri, Prashanthi , Lowe, Val J. , Petersen, Ronald C. , Vemuri, Prashanthi , Geda, Yonas E , Castillo, Anna M , Kremers, Walter K , Chamberlain, Alanna M. , Mielke, Michelle M. , Machulda, Mary M. , Jack, Clifford R. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | June 6, 2022 | Volume: 19 | Issue: 3 | Pages: 761-770

10.1002/alz.12702 | PMID 35666244 Get It

AbstractIntroductionWe investigated the association of the area deprivation index (ADI) with cognitive decline, mild cognitive impairment (MCI), and dementia in older adults (≥50 years old). ADI is a neighborhood socioeconomic disadvantage measure assessed at the census block group level.MethodsThe study included 4699 participants, initially without dementia, with available ADI values for 2015 and at least one study visit in 2008 through 2018. Using logistic regression and Cox proportional hazards models with age as the time scale, we assessed the odds for MCI and the risk for dementia, respectively.ResultsIn cognitively unimpaired (CU) adults at baseline, the risk for progression to dementia increased for every decile increase in the ADI state ranking (hazard ratio = 1.06, 95% confidence interval (1.01–1.11), P = .01). Higher ADI values were associated with subtly faster cognitive decline.DiscussionIn older CU adults, higher baseline neighborhood socioeconomic deprivation levels were associated with progression to dementia and slightly faster cognitive decline.Highlights The study used area deprivation index, a composite freely available neighborhood deprivation measure. Higher levels of neighborhood deprivation were associated with greater mild cognitive impairment odds. Higher neighborhood deprivation levels were associated with higher dementia risk.
Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post‐acute sequelae of SARS‐CoV‐2 infection (PASC)
Barry, John T., Bartels, Matthew N. , Fleming, Talya K. , McCauley, Mark , Neal, Jacqueline D., Pillarisetti, Jayasree , Sampsel, Sarah , Terzic, Carmen M., Tosto, Jenna, Fleming, Talya K , Sampsel, Sarah , Verduzco-Gutierrez, Monica , Whiteson, Jonathan H. , Azola, Alba Miranda , Blitshteyn, Svetlana , Silver, Julie K. , Verduzco‐Gutierrez, Monica , Putrino, David F.

Mayo Clinic

PM&R | June 3, 2022 | Volume: 14 | Issue: 7 | Pages: 855-878

10.1002/pmrj.12859 | PMID 35657351 Get It

EPCT-04. Stereotactic biopsy split-course radiation therapy for diffuse midline glioma of the pons (SPORT-DMG): Early phase II enrolling clinical trial
Cunningham, Danielle, Schwartz, Jonathan , Khatua, Soumen , Laack, Nadia, Silvera, V. Michelle , Brinkmann, Debra H. , Pafundi, Deanna, Keating, Gesina F. , Mahajan, Anita , Guérin, J. , Johnson, Derek R. , Ahmed, Safia K. , Raghunathan, Aditya , Giannini, Caterina , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: i36-i36

10.1093/neuonc/noac079.132 Get It

Abstract Diffuse midline glioma (DMG) of the pons remains the leading cause of death among pediatric patients with brain tumors, despite numerous attempts to intensify treatment. While standard treatment includes 54Gy in 30 fractions of radiation over six weeks of time, nearly all patients progress within the treatment field, and many experience symptomatic radionecrosis with steroid dependence. Symptom improvement typically begins after 20Gy to the tumor. Both hypofractionation and reirradiation after recurrence have been found to be safe for patients with DMG. Our study aims to enroll patients with newly diagnosed pontine DMG aged >1 year (no maximum age), and collect molecular information about DMG via stereotactic biopsy, followed by a short 2 week course of 25Gy in 10 fractions of radiation, with volumes guided by MRI with tractography reconstruction and FDOPA PET radiotracer uptake. Patients are followed closely and can complete the 25Gy in 10 fraction radiation course up to 3 times total for meeting radiographic and clinical progression criteria. Our primary endpoint is to estimate the time to progression from diagnosis to after receiving the second 25Gy course, and to compare this to the historical 7 month standard from diagnosis to progression after one 54Gy course. We aim to improve the time interval where patients are asymptomatic at home while minimizing time receiving daily treatments. Other endpoints will include the patient quality of life, caregiver quality of life, PFS intervals after each course, overall survival, and toxicity.
GCT-05. Multi-institutional analysis of treatment modalities in metastatic germinoma in children
MacDonald, S., Reiners, Stephanie, Govender, Dinisha , Nagabushan, Sumanth , Schwartz, Jonathan , Foo, Jen Chun , Rajagopal, Revathi, Perkins, Stephanie M., Zaghloul, Mohamed S. , Abdelhaleem, Nada A, El‐Ayadi, Moatasem , Abdelbaki, Mohamed S , Shatara, Margaret , Abu-Arja, Mohammad H , Gorsi, Hamza S. , Dholaria, Hetal , Rajagopal, Revathi , Bartels, Ute

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: i54-i55

10.1093/neuonc/noac079.199 Get It

Abstract BACKGROUND: Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors, with germinoma accounting for two-thirds of cases. Neoadjuvant chemotherapy with response-based reduced radiotherapy dose and field has become the standard management of localized CNS germinomas, however, treatment of primary metastatic disease has remained controversial. Furthermore, there is limited published research on the use of neoadjuvant chemotherapy in primary metastatic germinoma. METHODS: We performed a retrospective multi-institutional data collection and analysis of patients diagnosed with metastatic germinoma since 2000 to assess the overall survival (OS) and event-free survival (EFS) of the different treatment modalities administered. RESULTS: We identified 78 patients with germinoma, in two tertiary care centers, of which nine patients (11.5%; eight males) had metastatic disease. The median age at presentation was 13.3 years. All patients had a biopsy at presentation confirming the diagnosis. Three patients had positive CSF cytology (M1). Six patients received craniospinal irradiation (CSI) with boost to primary and metastatic sites, of which five patients received total CSI dose of 24 Gy, while the dose was unknown for one patient. One patient required one cycle of chemotherapy prior to CSI due to worsening visual changes, which subsequently resolved. One patient received two cycles followed by whole ventricular irradiation (WVI) of 23.4 Gy with a boost to the primary bed. One patient received WVI without neoadjuvant chemotherapy. One patient developed anoxic brain injury and only received chemotherapy. He died of recurrent progressive disease 15 months post-diagnosis. The median follow-up time was 77.5 months (range 15-130.5 months), with an OS of 88.9%. Further multi-institutional data collection and analysis is underway and will be presented at the meeting. CONCLUSION: We anticipate our results may elucidate the role of neoadjuvant chemotherapy in the treatment of metastatic germinoma, and whether when combined with lower CSI doses did not compromise EFS/OS.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Campo, Elı́as , Jaffe, Elaine S. , Cook, James R. , Quintanilla‐Martínez, Leticia , Brousset, Pierre , Cerroni, Lorenzo , Dirnhofer, Stefan , Friedberg, Jonathan W. , King, Rebecca L., Miguel, Jesús F. San , Seymour, John F. , Advani, Ranjana H. , Ansell, Stephen M. , Au, Wing-Yan, Bergsagel, Leif, Cohen, Jeffrey I. , d’Amore, Francesco, Ghobrial, Irene M. , Kim, Won-Seog, Kumar, Shaji , LaCasce, Ann S. , Laurent, Camille , Lenz, Georg, Leonard, John P. , Link, Michael P., López‐Guillermo, Armando , Mateos, María‐Victoria , Melnick, Ari , Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid , Pro, Barbara, Sander, Birgitta , Smith, Sonali M. , Staudt, Louis M. , Thieblemont, Catherine, Tousseyn, Thomas , Wilson, Wyndham H., Yoshino, Tadashi, Dreyling, Martin , Winter, Jane N., Bergsagel, P. Leif , Dirnhofer, S , Bergsagel, P. Leif , Brousset, Pierre , Dogan, Ahmet , Feldman, Andrew L , Ghia, Paolo , Salles, Gilles A , San-Miguel, Jesus , Seymour, John F , Treon, Steven , Vose, Julie , Zucca, Emanuele , Barrionuevo, Carlos , Davies, Andrew , Falini, Brunangelo , Ghobrial, Irene M , Goodlad, John R , Gribben, John G. , Hsi, Eric D , Kahl, Brad S , Kumar, Shaji K , LaCasce, Ann Steward , Mateos, María-Victoria , Macintyre, Elizabeth , Melnick, Ari , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel , Rajkumar, Vincent, Shipp, Margaret Ann , Smith, Sonali M , Zinzani, Pier Luigi , Dreyling, Martin , Scott, David W , Zelenetz, Andrew D , Jaffe, Elaine S , Campo, Elías , Advani, Ranjana H , Quintanilla-Martinez, Leticia , Swerdlow, Steven H. , Anderson, Kenneth C. , Leval, Laurence de , Doǧan, Ahmet , Feldman, Andrew L. , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Horwitz, Steven M. , Salles, Gilles , Treon, Steven P. , Vose, Julie M. , Zucca, Emanuele , Chan, Wing C., Davies, Andrew , Falini, Brunangelo , Hsi, Eric D. , Kahl, Brad S. , Kim, Won Seog , Lenz, Georg , Macintyre, Elizabeth , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel Á. , Rajkumar, S. Vincent , Rosen, Steven T. , Sehn, Laurie H. , Thiéblemont, Catherine , Wilson, Wyndham H. , Yoshino, Tadashi, Zinzani, Pier Luigi , Scott, David W. , Winter, Jane N. , Zelenetz, Andrew D.

Mayo Clinic

Blood | June 2, 2022 | Volume: 140 | Issue: 11 | Pages: 1229-1253

10.1182/blood.2022015851 | PMID 35653592 Get It

Abstract Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies, Faith E. , Pawlyn, Charlotte , Usmani, Saad Z. , Miguel, Jesús F. San , Boyle, Eileen M. , Corre, Jill , Auclair, Daniel , Cho, Hearn Jay , Sonneveld, Pieter , Stewart, A. Keith , Bergsagel, P. Leif , Kaiser, Martin , Morgan, Kathryn E., Ghobrial, Irene M. , Orlowski, Robert Z. , Caers, Joseph, Chari, Ajai , Walker, Brian A. , Kumar, Shaji , Costa, Luciano J. , Bergsagel, P. Leif , San-Miguel, Jesus , Boyle, Eileen M , Corre, Jill , Cho, Hearn Jay , Kaiser, Martin F , Keats, Jonathan J , Mikhael, Joseph R , Orlowski, Robert Z. , Landgren, C Ola , Gay, Francesca , Chng, Wee Joo , Chari, Ajai , Walker, Brian A , Kumar, Shaji K , Costa, Luciano J , Anderson, Kenneth C , Morgan, Gareth J , Davies, Faith E , Ghobrial, Irene M , Pawlyn, Charlotte , Usmani, Saad , Einsele, Hermann , Lonial, Sagar , Weisel, Katja C , Keats, Jonathan J. , Mıkhael, Joseph , Landgren, Ola , Gay, Francesca , Chng, Wee Joo , Anderson, Kenneth C. , Morgan, Gareth J.

Mayo Clinic

Blood Cancer Discovery | June 2, 2022 | Volume: 3 | Issue: 4 | Pages: 273-284

10.1158/2643-3230.bcd-21-0205 | PMID 35653112 Get It

Summary: The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
0640 North American Prodromal Synucleinopathy Consortium: Baseline characteristics in 251 patients with REM Sleep Behavior Disorder
Lim, Miranda M. , Keil, Allison , Bliwise, Don, Gagnon, Jean‐François , McLeland, Jennifer , Ju, Yo‐El S. , Elliott, Jonathan E. , Avidan, Alon Y. , Howell, Michael J. , Huddleston, Daniel E. , Postuma, Ronald B. , Louis, Erik K. St. , Videnovic, Aleksandar , Boeve, Bradley F.

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A281-A282

10.1093/sleep/zsac079.637 Get It

Abstract Introduction Introduction: Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) is characterized by a lack of muscle atonia during REM sleep with dream enactment. RBD is regarded as a prodromal synucleinopathy as a high proportion of patients eventually phenoconvert to Parkinson’s Disease and related synucleinopathies, suggesting RBD may be an early non-motor symptom of disease. Accordingly, patients with RBD are ideally situated to test potential therapeutic interventions to prevent phenoconversion to synucleinopathy. However, RBD itself, and associated patient registries, are rare. The North American Prodromal Synucleinopathy Consortium (NAPS) establishes a multisite registry of RBD patients with standardized neurological, neuropsychiatric, and neuropsychological assessments and biomarker collection. The present work reports baseline characteristics of this RBD patient database at its current state. Methods Methods: Participants >18 years of age with overnight polysomnogram-confirmed RBD by ICSD-3 criteria who did not meet criteria for the diagnosis of PD, dementia, MSA, or narcolepsy were enrolled from 10 sites across North America (8/2018 to 4/2021). Data collection included family and personal history of RBD and related symptoms, as well as standardized assessments related to cognitive, motor, sensory and autonomic function. Additionally, all subjects have contributed blood, and a subset of subjects have contributed cerebrospinal fluid samples to the National Centralized Repository for Alzheimer's Disease and Related Dementias for future analysis. Results Results: A total of n=251 participants were enrolled. Outcomes are reported based on sex (n=202 male, n=49 female). Data were further examined based on participants’ history of antidepressant use (n=142 with, n=103 without) and based on participants’ extent of synucleinopathy burden (n=70 defined as isolated RBD, n=181 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Any observed sex differences among the data did not persist after correction for antidepressant use. Conclusion Conclusions: This prospective, cross-sectional data on history, demographic, cognitive, motor, sensory, and autonomic function in n=251 participants with RBD highlight the lack of sex differences and the high preponderance of concomitant neurological abnormalities with RBD, and provide a valuable registry for future longitudinal studies and neuroprotective clinical trials. Support (If Any) NIH NIA R34 AG056639 (YJ, BB)
0264 Sleepiness in cognitively unimpaired older adults is associated with CSF biomarkers of inflammation and axonal integrity
Przybelski, Scott A. , Boeve, Bradley, Petersen, Ronald, Graff‐Radford, Jonathan , Carvalho, Diego Z. , Louis, Erik K. St. , Morgenthaler, Timothy I. , Jack, Clifford R. , Vemuri, Prashanthi , Mielke, Michelle M.

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A119-A119

10.1093/sleep/zsac079.262 Get It

Abstract Introduction We have previously shown that older adults with excessive daytime sleepiness (EDS) appear to be more vulnerable to longitudinal amyloid PET accumulation before the onset of the dementia. It remains unclear whether this vulnerability is specific to amyloid or extends to other biomarkers of Alzheimer’s disease pathology, or axonal integrity and inflammation, which can also contribute to neurodegeneration and cognitive changes. Methods For this cross-sectional analysis, we identified 260 cognitively unimpaired adults (>60 years old) without neurologic disorder who underwent CSF quantification of AD biomarkers (CSF Aβ-42, p-tau181, p-tau217) along with at least one other biomarker of interest (neurofilament light chain [NfL], IL-6, IL-10, and TNF-α) from the Mayo Clinic Study of Aging – a longitudinal population-based cohort in Olmsted County, Minnesota. CSF biomarkers were available in 251-260 individuals, depending on the biomarker. We fit linear regression models to assess whether the CSF biomarkers were associated with sleepiness as measured by the Epworth Sleepiness Scale (ESS), after controlling for age, sex, APOE4 genotype, BMI, hypertension, dyslipidemia, and OSA diagnosis (by chart review). Results Higher ESS scores were independently associated with higher CSF IL-6 and NfL, but not with the other biomarkers in the whole sample. For every single-point increase in the ESS score, there was a .008 ([95% CI .001-.016], p=0.033) increase in the log of IL-6 and .01 ([95% CI .002-.018], p=0.016) increase in the log of NfL. A sensitivity analysis showed a correlation between ESS scores and log of p-tau/Aβ-42 ratio only in participants with abnormal ratio (>0.023), after controlling for APOE4 (partial r=.27, p=039). Conclusion Our results corroborate previous literature suggesting that higher inflammatory milieu reflected by increased CSF IL-6 is associated with sleepiness. The association between NfL and sleepiness suggests that sleepiness may be related to disturbed connectivity due to axonal damage. Alternatively, NfL may be a surrogate of active axonal injury associated with more disrupted sleep. A correlation between sleepiness and CSF p-tau/ab-42 ratio was only seen in patients with abnormal ratio, suggesting a stronger association between sleepiness and AD pathology as the disease progresses, possibly because AD pathology worsens sleep quality and/or vice-versa. Support (If Any) NIH/NIA